Leo’s IL-13 mAb hits in atopic dermatitis; how it stacks up against Dupixent remains a question mark

Over a year after the primary completion of tralokinumab’s Phase III studies, Leo Pharma has said the anti-IL-13 mAb met the primary endpoint in all three trials to treat moderate-to-severe atopic dermatitis without divulging details.

When the data are announced, the efficacy bar to beat will be the benefit seen with Dupixent dupilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NASDAQ:SNY)...